OncoZenge AB (publ) (FRA:8LY)

Market Cap	9.47M +37.0%
Revenue (ttm)	6.47K -97.4%
Net Income	-2.11M
EPS	-0.17
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.6530
Previous Close	0.6350
Day's Range	0.6530 - 0.6530
52-Week Range	0.4480 - 0.7540
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2026

About OncoZenge AB

OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 1
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8LY

Financial Performance

In 2025, OncoZenge AB's revenue was 2.78 million, an increase of 278300.00% compared to the previous year's 1,000. Losses were -15.94 million, 83.5% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error